Base de dados : MEDLINE
Pesquisa : B03.440.450.600.450.330.150 [Categoria DeCS]
Referências encontradas : 1056 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 106 ir para página                         

  1 / 1056 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27774610
[Au] Autor:Lee S; Kim HW; Kim KH
[Ad] Endereço:Center for Vaccine Evaluation and Study, Medical Research Institute, Seoul, Republic of Korea.
[Ti] Título:Functional antibodies to Haemophilus influenzae type B, Neisseria meningitidis, and Streptococcus pneumoniae contained in intravenous immunoglobulin products.
[So] Source:Transfusion;57(1):157-165, 2017 01.
[Is] ISSN:1537-2995
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Intravenous immunoglobulin G (IVIG) replacement therapy is used to prevent invasive infections in patients with primary antibody deficiency (PAD). However, few studies have functionally evaluated specific antibodies against encapsulated bacteria that cause invasive infection in patients with PAD. In this study, functional antibodies against Haemophilus influenzae type b (Hib), Streptococcus pneumoniae (pneumococci), and Neisseria meningitidis (meningococci) in IVIG therapy were evaluated. STUDY DESIGN AND METHODS: Sixteen lots of IVIG products prepared by two Korean manufacturers (Products A and B) were evaluated. The functional antibodies were measured by serum bactericidal assay for Hib and four meningococcal serogroups and by multiplexed opsonophagocytic assay for 26 pneumococcal serotypes. The estimated trough levels of antibodies against Hib, pneumococcus, and meningococcus were calculated to determine whether the usual IVIG dose is appropriate for protecting patients with PAD. RESULTS: The functional antibody levels for Hib were similar in all of the IVIG products. In contrast, serum bacterial indices of meningococcal serogroups A and Y showed significant differences between products A and B. Opsonic indices to pneumococci varied depending on the serotype in each IVIG product. The estimated trough levels of antibodies against Hib, pneumococcus, and meningococcus exceeded the protective levels in most of the IVIG products except for the antibodies against two pneumococcal serotypes. CONCLUSION: Most of the tested commercial IVIG products had sufficient functional antibodies against Hib, pneumococcus, and meningococcus to protect patients with PAD receiving IVIG treatment. Regular and continuous evaluation of IVIG products is necessary to maintain an optimal therapeutic effect.
[Mh] Termos MeSH primário: Anticorpos Antibacterianos/imunologia
Haemophilus influenzae tipo b/imunologia
Imunoglobulinas Intravenosas/imunologia
Neisseria meningitidis/imunologia
Streptococcus pneumoniae/imunologia
[Mh] Termos MeSH secundário: Seres Humanos
República da Coreia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies, Bacterial); 0 (Immunoglobulins, Intravenous)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE
[do] DOI:10.1111/trf.13869


  2 / 1056 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28301990
[Au] Autor:Lundbo LF; Benfield T
[Ad] Endereço:a Department of Infectious Diseases , Copenhagen University Hospital , Hvidovre , Denmark.
[Ti] Título:Risk factors for community-acquired bacterial meningitis.
[So] Source:Infect Dis (Lond);49(6):433-444, 2017 Jun.
[Is] ISSN:2374-4243
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Bacterial meningitis is a significant burden of disease and mortality in all age groups worldwide despite the development of effective conjugated vaccines. The pathogenesis of bacterial meningitis is based on complex and incompletely understood host-pathogen interactions. Some of these are pathogen-specific, while some are shared between different bacteria. METHODS: We searched the database PubMed to identify host risk factors for bacterial meningitis caused by the pathogens Streptococcus pneumoniae, Neisseria meningitidis and Haemophilus influenzae type b, because they are three most common causative bacteria beyond the neonatal period. RESULTS: We describe a number of risk factors; including socioeconomic factors, age, genetic variation of the host and underlying medical conditions associated with increased susceptibility to invasive bacterial infections in both children and adults. CONCLUSIONS: As conjugated vaccines are available for these infections, it is of utmost importance to identify high risk patients to be able to prevent invasive disease.
[Mh] Termos MeSH primário: Infecções Comunitárias Adquiridas/etiologia
Infecções Comunitárias Adquiridas/microbiologia
Meningites Bacterianas/etiologia
Meningites Bacterianas/microbiologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Fatores Etários
Vacinas Bacterianas/administração & dosagem
Criança
Pré-Escolar
Infecções Comunitárias Adquiridas/prevenção & controle
Feminino
Haemophilus influenzae tipo b/isolamento & purificação
Interações Hospedeiro-Patógeno
Seres Humanos
Lactente
Masculino
Meningites Bacterianas/prevenção & controle
Meningite por Haemophilus/microbiologia
Meningite por Haemophilus/prevenção & controle
Meningite Meningocócica/microbiologia
Meningite Meningocócica/prevenção & controle
Meningite Pneumocócica/microbiologia
Meningite Pneumocócica/prevenção & controle
Neisseria meningitidis/isolamento & purificação
Fatores de Risco
Fatores Socioeconômicos
Streptococcus pneumoniae/isolamento & purificação
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Bacterial Vaccines)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170406
[Lr] Data última revisão:
170406
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170318
[St] Status:MEDLINE
[do] DOI:10.1080/23744235.2017.1285046


  3 / 1056 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28277801
[Au] Autor:Wang YX; Tao H; Hu JL; Li JX; Dai WM; Sun JF; Liu P; Tang J; Liu WY; Zhu FC
[Ad] Endereço:a School of Public Health , Southeast University , Nanjing , PR China.
[Ti] Título:The immunogenicity and safety of a Hib-MenAC vaccine: a non-inferiority randomized, observer-blind trial in infants aged 3-5 months.
[So] Source:Expert Rev Vaccines;16(5):515-524, 2017 May.
[Is] ISSN:1744-8395
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The objective of this study was to evaluate the immunogenicity and safety of the novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroup A and C-tetanus toxoid conjugate vaccine (Hib-MenAC). METHODS: We conducted a non-inferiority, randomized, observer-blind, positive control clinical trial in 900 healthy infants aged between 3-5 months in Funing County, Jiangsu Province, China. Participants were randomly allocated, in a ratio of 2:1 (block = 6), to receive experimental combined Hib-MenAC vaccines co-administrated with placebo or the co-administration of licensed Hib vaccine and MenAC vaccine, according to a three-dose immunization schedule. The seroconversion of antibody titer against meningococcal serogroups A, C and Hib was the primary endpoint. RESULTS: The experimental vaccines was non-inferior to the licensed two control vaccines. Participants receiving experimental Hib-MenAC vaccines showed a seroconversion rate of 99.0%, 96.1% and 97.7% for rSBA-MenA, rSBA-MenC and anti-PRP antibodies, respectively. The Hib-MenAC vaccine did not result in an increase in adverse reaction, and no serious adverse event was judged to be related to the vaccination. CONCLUSIONS: The novel combined Hib-MenAC conjugate vaccine was safe and highly immunogenic in infants aged between 3 to 5 months.
[Mh] Termos MeSH primário: Vacinas Anti-Haemophilus/imunologia
Vacinas Meningocócicas/efeitos adversos
Vacinas Meningocócicas/imunologia
[Mh] Termos MeSH secundário: Anticorpos Antibacterianos/sangue
China
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/epidemiologia
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/patologia
Feminino
Vacinas Anti-Haemophilus/administração & dosagem
Haemophilus influenzae tipo b/imunologia
Seres Humanos
Lactente
Masculino
Vacinas Meningocócicas/administração & dosagem
Neisseria meningitidis Sorogrupo A/imunologia
Neisseria meningitidis Sorogrupo C/imunologia
Placebos/administração & dosagem
Método Simples-Cego
Toxoide Tetânico/administração & dosagem
Toxoide Tetânico/efeitos adversos
Toxoide Tetânico/imunologia
Resultado do Tratamento
Vacinas Combinadas/administração & dosagem
Vacinas Combinadas/efeitos adversos
Vacinas Combinadas/imunologia
Vacinas Conjugadas/administração & dosagem
Vacinas Conjugadas/efeitos adversos
Vacinas Conjugadas/imunologia
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Antibodies, Bacterial); 0 (Haemophilus Vaccines); 0 (Meningococcal Vaccines); 0 (Placebos); 0 (Tetanus Toxoid); 0 (Vaccines, Combined); 0 (Vaccines, Conjugate)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170425
[Lr] Data última revisão:
170425
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170310
[St] Status:MEDLINE
[do] DOI:10.1080/14760584.2017.1303380


  4 / 1056 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28166256
[Au] Autor:Qu F; Weschler LB; Sun Y; Sundell J
[Ad] Endereço:China Meteorological Administration Training Centre, China Meteorological Administration, Beijing, China.
[Ti] Título:High pneumonia lifetime-ever incidence in Beijing children compared with locations in other countries, and implications for national PCV and Hib vaccination.
[So] Source:PLoS One;12(2):e0171438, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To compare the proportion of Beijing children who have ever had pneumonia (%Pneumonia) to those in other locations, and to estimate by how much national vaccine coverage with Pneumococcal Conjugate Vaccine (PCV) and Haemophilus Influenzae Type b (Hib) could reduce Beijing %Pneumonia. METHODS: %Pneumonia was obtained for each age group from 1 to 8 years inclusive from 5,876 responses to a cross-sectional questionnaire. Literature searches were conducted for world-wide reports of %Pneumonia. Previous vaccine trials conducted worldwide were used to estimate the pneumococcal (S. pneumoniae) and Hib (H. influenzae) burdens and %Pneumonia as well as the potential for PCV and Hib vaccines to reduce Beijing children's %Pneumonia. FINDINGS: The majority of pneumonia cases occurred by the age of three. The cumulative %Pneumonia for 3-8 year-old Beijing children, 26.9%, was only slightly higher than the 25.4% for the discrete 3 year-old age group, similar to trends for Tianjin (China) and Texas (USA). Beijing's %Pneumonia is disproportionally high relative to its Gross National Income (GNI) per capita, and markedly higher than %Pneumonia in the US and other high GNI per capita countries. Chinese diagnostic guidelines recommend chest X-ray confirmation while most other countries discourage it in favor of clinical diagnosis. Literature review shows that chest X-ray confirmation returns far fewer pneumonia diagnoses than clinical diagnosis. Accordingly, Beijing's %Pneumonia is likely higher than indicated by raw numbers. Vaccine trials suggest that national PCV and Hib vaccination could reduce Beijing's %Pneumonia from 26.9% to 19.7% and 24.9% respectively. CONCLUSION: National PCV and Hib vaccination programs would substantially reduce Beijing children's pneumonia incidence.
[Mh] Termos MeSH primário: Vacinas contra Influenza/imunologia
Vacinas Pneumocócicas/imunologia
Pneumonia/epidemiologia
Pneumonia/prevenção & controle
Vacinação
Vacinas Conjugadas/imunologia
[Mh] Termos MeSH secundário: Fatores Etários
Pequim/epidemiologia
Criança
Pré-Escolar
Feminino
Haemophilus influenzae tipo b/imunologia
Seres Humanos
Incidência
Lactente
Masculino
Pneumonia/etiologia
Vigilância da População
Streptococcus pneumoniae/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Influenza Vaccines); 0 (Pneumococcal Vaccines); 0 (Vaccines, Conjugate)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170825
[Lr] Data última revisão:
170825
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170207
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0171438


  5 / 1056 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28088246
[Au] Autor:Teimouri F; Kebriaeezadeh A; Zahraei SM; Gheiratian M; Nikfar S
[Ad] Endereço:Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
[Ti] Título:Budget impact analysis of vaccination against Haemophilus influenzae type b as a part of a Pentavalent vaccine in the childhood immunization schedule of Iran.
[So] Source:Daru;25(1):1, 2017 Jan 14.
[Is] ISSN:2008-2231
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Health decision makers need to know the impact of the development of a new intervention on the public health and health care costs so that they can plan for economic and financial objectives. The aim of this study was to determine the budget impact of adding Haemophilus influenzae type b (Hib) as a part of a Pentavalent vaccine (Hib-HBV-DTP) to the national childhood immunization schedule of Iran. METHODS: An excel-based model was developed to determine the costs of including the Pentavalent vaccine in the national immunization program (NIP), comparing the present schedule with the previous one (including separate DTP and hepatitis B vaccines). The total annual costs included the cost of vaccination (the vaccine and syringe) and the cost of Hib treatment. The health outcome was the estimated annual cases of the diseases. The net budget impact was the difference in the total annual cost between the two schedules. Uncertainty about the vaccine effectiveness, vaccination coverage, cost of the vaccine, and cost of the diseases were handled through scenario analysis. RESULTS: The total cost of vaccination during 5 years was $18,060,463 in the previous program and $67,774,786 in the present program. Inclusion of the Pentavalent vaccine would increase the vaccination cost about $49 million, but would save approximately $6 million in the healthcare costs due to reduction of disease cases and treatment costs. The introduction of the Pentavalent vaccine resulted in a net increase in the healthcare budget expenditure across all scenarios from $43.4 million to $50.7 million. CONCLUSIONS: The results of this study showed that the inclusion of the Pentavalent vaccine in the NIP of Iran had a significant impact on the health care budget and increased the financial burden on the government. Budget impact of including Pentavalent vaccine in the national immunization schedule of Iraná…Ÿ.
[Mh] Termos MeSH primário: Vacina contra Difteria, Tétano e Coqueluche/economia
Vacinas Anti-Haemophilus/economia
Haemophilus influenzae tipo b/imunologia
Vacinas contra Hepatite B/economia
Programas Nacionais de Saúde/economia
Vacinas Combinadas/economia
[Mh] Termos MeSH secundário: Pré-Escolar
Infecções por Haemophilus/tratamento farmacológico
Infecções por Haemophilus/economia
Custos de Cuidados de Saúde
Seres Humanos
Esquemas de Imunização
Irã (Geográfico)
Seringas/economia
Vacinação/economia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Diphtheria-Tetanus-Pertussis Vaccine); 0 (Haemophilus Vaccines); 0 (Hepatitis B Vaccines); 0 (Vaccines, Combined)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170116
[St] Status:MEDLINE
[do] DOI:10.1186/s40199-017-0166-0


  6 / 1056 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28077083
[Au] Autor:Soysal A; Toprak DG; Türkoglu S; Bakir M
[Ad] Endereço:Division of Pediatric Infectious Diseases, Marmara University Medical Faculty Department of Pediatrics, Istanbul, Turkey. asoysal@marmara.edu.tr.
[Ti] Título:Evaluation of the line probe assay for the rapid detection of bacterial meningitis pathogens in cerebrospinal fluid samples from children.
[So] Source:BMC Microbiol;17(1):14, 2017 Jan 11.
[Is] ISSN:1471-2180
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The aim of this study is to compare the diagnostic performance of the line probe assay (LPA) with conventional multiplex polymerase chain reaction (PCR) for Streptococcus pneumoniae as well as real-time PCR for Neisseria meningitidis and Haemophilus influenzae type b (Hib) in cerebrospinal fluid (CSF) samples from children during the multicenter national surveillance of bacterial meningitis between the years 2006 and 2009 in Turkey. RESULTS: During the study period 1460 subjects were enrolled and among them 841 (57%) met the criteria for probable bacterial meningitis. The mean age of subjects was 51 ± 47 months (range, 1-212 months). We performed the line probe assay in 751 (89%) CSF samples of 841 probable bacterial meningitis cases, of whom 431 (57%) were negative, 127 (17%) were positive for S. pneumoniae, 53 (7%) were positive for H. influenzae type b, and 41 (5%) were positive for N. meningitidis. The LPA was positive in 19 of 23 (82%) S. pneumoniae samples, 4 of 6 (67%) N. meningitidis samples and 2 of 2 (100%) Hib samples in CSF culture-positive cases. The specificity of the LPA for all of S. pneumoniae, H. influenzae type b, and N. meningitidis was 88% (95% CI: 85-91%), when using the standard PCR as a reference. The specificity of LPA for each of S. pneumoniae, H. influenzae type b, and N. meningitidis was 93% (95% CI: 89-95%), 96% (95% CI: 94-98%), and 99% (95% CI: 97-99%), respectively. For all of S. pneumoniae, H. influenzae type b and N. meningitidis the sensitivity of the LPA was 76% (95% CI: 70-82%) and for each of S. pneumoniae, H. influenzae type b and N. meningitidis was 72% (95% CI:63-79%), 88% (95% CI: 73-95%), and 81% (95% CI:67-92%), respectively. CONCLUSIONS: The LPA assay can be used to detect common bacterial meningitis pathogens in CSF samples, but the assay requires further improvement.
[Mh] Termos MeSH primário: Bactérias/genética
Bactérias/isolamento & purificação
Técnicas de Tipagem Bacteriana/métodos
Líquido Cefalorraquidiano/microbiologia
Meningites Bacterianas/líquido cefalorraquidiano
Meningites Bacterianas/diagnóstico
Meningites Bacterianas/microbiologia
[Mh] Termos MeSH secundário: Adolescente
Criança
Pré-Escolar
DNA Bacteriano
Feminino
Haemophilus influenzae tipo b/genética
Haemophilus influenzae tipo b/isolamento & purificação
Seres Humanos
Lactente
Masculino
Meningite por Haemophilus/epidemiologia
Meningite por Haemophilus/microbiologia
Meningite Meningocócica/epidemiologia
Meningite Meningocócica/microbiologia
Meningite Pneumocócica/epidemiologia
Meningite Pneumocócica/microbiologia
Técnicas de Sonda Molecular
Reação em Cadeia da Polimerase Multiplex/métodos
Neisseria meningitidis/genética
Neisseria meningitidis/isolamento & purificação
Reação em Cadeia da Polimerase/métodos
Reação em Cadeia da Polimerase em Tempo Real
Sensibilidade e Especificidade
Streptococcus pneumoniae/genética
Streptococcus pneumoniae/isolamento & purificação
Turquia/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (DNA, Bacterial)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170831
[Lr] Data última revisão:
170831
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170113
[St] Status:MEDLINE
[do] DOI:10.1186/s12866-016-0834-0


  7 / 1056 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28058825
[Ti] Título:Status of new vaccine introduction ­ worldwide, September 2016.
[Ti] Título:Situation relative à l'introduction de nouveaux vaccins à l'échelle mondiale, septembre 2016..
[So] Source:Wkly Epidemiol Rec;92(1):1-8, 2017 01 06.
[Is] ISSN:0049-8114
[Cp] País de publicação:Switzerland
[La] Idioma:eng; fre
[Mh] Termos MeSH primário: Saúde Global
Programas de Imunização/estatística & dados numéricos
Vacinas/provisão & distribuição
[Mh] Termos MeSH secundário: Adolescente
Criança
Pré-Escolar
Vacinas Anti-Haemophilus/provisão & distribuição
Haemophilus influenzae tipo b
Vacinas contra Hepatite B/provisão & distribuição
Seres Humanos
Lactente
Vacina contra Sarampo/provisão & distribuição
Vacinas contra Papillomavirus/provisão & distribuição
Vacinas Pneumocócicas/provisão & distribuição
Vacinas contra Rotavirus/provisão & distribuição
Vacina contra Rubéola/provisão & distribuição
Organização Mundial da Saúde
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Haemophilus Vaccines); 0 (Hepatitis B Vaccines); 0 (Measles Vaccine); 0 (Papillomavirus Vaccines); 0 (Pneumococcal Vaccines); 0 (Rotavirus Vaccines); 0 (Rubella Vaccine); 0 (Vaccines)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170131
[Lr] Data última revisão:
170131
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170107
[St] Status:MEDLINE


  8 / 1056 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28035545
[Au] Autor:Syed YY
[Ad] Endereço:Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand. demail@springer.com.
[Ti] Título:DTaP5-HB-IPV-Hib Vaccine (Vaxelis ): A Review of its Use in Primary and Booster Vaccination.
[So] Source:Paediatr Drugs;19(1):69-80, 2017 Feb.
[Is] ISSN:1179-2019
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Vaxelis is a fully liquid, ready-to-use, hexavalent vaccine approved in the EU for primary and booster vaccination in infants and toddlers from the age of 6 weeks against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and invasive diseases caused by Haemophilus influenzae type b (Hib). It contains diphtheria and tetanus toxoids, five acellular pertussis antigens, recombinant hepatitis B virus surface antigen produced in the yeast, Saccharomyces cerevisiae, inactivated poliovirus, and the Hib polysaccharide (polyribosylribitol phosphate) conjugated to the outer membrane protein complex of Neisseria meningitidis. In pivotal clinical studies, Vaxelis was highly immunogenic for all its component toxoids/antigens when administered by three different schedules. Primary endpoints of seroprotection or vaccine response rates with Vaxelis met the predefined acceptability criteria and were noninferior to those with comparator vaccines (Infanrix hexa or Pentacel plus Recombivax HB ). Limited data indicate that immune responses to Vaxelis in preterm infants were generally similar to those seen in the overall population. Vaxelis can be coadministered with a number of common childhood vaccines. In clinical studies, Vaxelis was generally well tolerated with a tolerability profile similar to that of the comparator vaccines. Available clinical data indicate that Vaxelis is a new hexavalent vaccine option for immunization against several serious childhood infectious diseases.
[Mh] Termos MeSH primário: Vacina contra Difteria, Tétano e Coqueluche
Vacinas Anti-Haemophilus
Vacinas contra Hepatite B
Vacina Antipólio de Vírus Inativado
Vacinas Combinadas
[Mh] Termos MeSH secundário: Difteria/prevenção & controle
Vacinas contra Difteria, Tétano e Coqueluche Acelular
Infecções por Haemophilus/prevenção & controle
Haemophilus influenzae tipo b/imunologia
Hepatite B/prevenção & controle
Seres Humanos
Imunização Secundária
Lactente
Poliomielite/prevenção & controle
Tétano/prevenção & controle
Vacinação
Vacinas Sintéticas
Coqueluche/prevenção & controle
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Diphtheria-Tetanus-Pertussis Vaccine); 0 (Diphtheria-Tetanus-acellular Pertussis Vaccines); 0 (Haemophilus Vaccines); 0 (Hepatitis B Vaccines); 0 (Poliovirus Vaccine, Inactivated); 0 (Recombivax HB); 0 (Vaccines, Combined); 0 (Vaccines, Synthetic); 0 (Vaxelis); 0 (pentacel)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:171113
[Lr] Data última revisão:
171113
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161231
[St] Status:MEDLINE
[do] DOI:10.1007/s40272-016-0208-y


  9 / 1056 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27930540
[Au] Autor:Soothill G; Darboe S; Bah G; Bolarinde L; Cunnington A; Anderson ST
[Ad] Endereço:aMRC Unit The Gambia, Atlantic Boulevard, Fajara, The Gambia bRoyal Free Hospital, Pond St, London, UK cSection of Paediatrics, Department of Medicine, Imperial College London, London, UK.
[Ti] Título:Invasive bacterial infections in Gambians with sickle cell anemia in an era of widespread pneumococcal and hemophilus influenzae type b vaccination.
[So] Source:Medicine (Baltimore);95(49):e5512, 2016 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:There is relatively little data on the etiology of bacterial infections in patients with sickle cell anemia (SCA) in West Africa, and no data from countries that have implemented conjugate vaccines against both Streptococcus pneumoniae and Haemophilus influenzae type b (Hib).We conducted a retrospective analysis of SCA patients admitted to the Medical Research Council Unit, The Gambia, during a 5-year period when there was high coverage of Hib and Pneumococcal conjugate vaccination. We evaluated 161 admissions of 126 patients between April 2010 and April 2015.Pathogenic bacteria were identified in blood cultures from 11 of the 131 admissions that had cultures taken (8.4%, 95% CI 4.5-14.1%). The most frequent isolate was Salmonella Typhimurium (6/11; 54.5%), followed by Staphylococcus aureus (2/11; 18.2%) and other enteric Gram-negative pathogens (2/11; 18.2%) and there was 1 case of H influenzae non-type b bacteremia (1/11; 9.1%). There were no episodes of bacteremia caused by S pneumoniae or Hib.The low prevalence of S pneumoniae and Hib and the predominance of nontyphoidal Salmonella as a cause of bacteremia suggest the need to reconsider optimal antimicrobial prophylaxis and the empirical treatment regimens for patients with SCA.
[Mh] Termos MeSH primário: Anemia Falciforme
Infecções por Haemophilus/epidemiologia
Infecções Estreptocócicas/epidemiologia
[Mh] Termos MeSH secundário: Cápsulas Bacterianas
Vacinas Bacterianas/administração & dosagem
Feminino
Gâmbia/epidemiologia
Infecções por Haemophilus/etiologia
Infecções por Haemophilus/prevenção & controle
Vacinas Anti-Haemophilus/administração & dosagem
Haemophilus influenzae tipo b/imunologia
Seres Humanos
Masculino
Infecções Estreptocócicas/etiologia
Infecções Estreptocócicas/prevenção & controle
Streptococcus pneumoniae/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bacterial Vaccines); 0 (Haemophilus Vaccines); 0 (Haemophilus influenzae type b polysaccharide vaccine)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170224
[Lr] Data última revisão:
170224
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:161209
[St] Status:MEDLINE


  10 / 1056 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:27753766
[Au] Autor:Arya BK; Bhattacharya SD; Sutcliffe CG; Kumar Niyogi S; Bhattacharyya S; Hemram S; Moss WJ; Panda S; Saurav Das R; Mandal S; Robert D; Ray P
[Ad] Endereço:From the *School of Medical Science and Technology, Indian Institute of Technology (IIT), Kharagpur, West Bengal, India; †International Vaccine Access Center (IVAC) and Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; ‡Division of Epidemiology, National Institute of Cholera and Enteric Diseases (NICED)/ Indian Council of Medical Research, Kolkata, West Bengal, India; §Department of Pediatrics, Midnapore Medical College, Midnapore, West Bengal, India; and ¶Department of Health and Family Welfare, Hijli Rural Hospital, Kharagpur, West Bengal, India.
[Ti] Título:Impact of Haemophilus influenzae Type B Conjugate Vaccines on Nasopharyngeal Carriage in HIV-infected Children and Their Parents From West Bengal, India.
[So] Source:Pediatr Infect Dis J;35(11):e339-e347, 2016 Nov.
[Is] ISSN:1532-0987
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: In addition to reducing Haemophilus influenzae type b (Hib) disease in vaccinated individuals, the Hib conjugate vaccine (HibCV) has indirect effects; it reduces Hib disease in unvaccinated individuals by decreasing carriage. Human immunodeficiency virus (HIV)-infected children are at increased risk for Hib disease and live in families where multiple members may have HIV. The aim of this study is to look at the impact of 2 doses of the HibCV on nasopharyngeal carriage of Hib in HIV-infected Indian children (2-15 years) and the indirect impact on carriage in their parents. METHODS: This prospective cohort study was conducted in HIV-infected and HIV-uninfected families. Nasopharyngeal swabs were collected from children and parents before and after vaccination. HIV-infected children 2-15 years of age got two doses of HibCV and were followed up for 20 months. Uninfected children 2-5 years of age got 1 dose of HibCV as catch-up. RESULTS: 123 HIV-infected and 44 HIV-uninfected children participated. Baseline colonization in HIV-infected children was 13.8% and dropped to 1.8% (P = 0.002) at 20 months. Baseline carriage in HIV-uninfected children was 4.5% and dropped to 2.3% after vaccination (P = 0.3). HIV-infected parents had 12.3 times increased risk of Hib carriage if their child was colonized (P = 0.04) and had 9.3 times increased risk if their child had persistent colonization postvaccine (P = 0.05). No parent of HIV-uninfected children had Hib colonization at any point. Pneumococcal colonization was associated with increased Hib colonization. CONCLUSION: Making the HibCV available to HIV-infected children could interrupt Hib carriage in high-risk families.
[Mh] Termos MeSH primário: Cápsulas Bacterianas
Portador Sadio/epidemiologia
Infecções por HIV/epidemiologia
Infecções por Haemophilus/epidemiologia
Vacinas Anti-Haemophilus
Haemophilus influenzae tipo b
[Mh] Termos MeSH secundário: Adolescente
Portador Sadio/microbiologia
Portador Sadio/prevenção & controle
Portador Sadio/virologia
Criança
Pré-Escolar
Feminino
Infecções por HIV/microbiologia
Infecções por HIV/virologia
Infecções por Haemophilus/microbiologia
Infecções por Haemophilus/prevenção & controle
Infecções por Haemophilus/virologia
Seres Humanos
Índia/epidemiologia
Masculino
Pais
Estudos Prospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Haemophilus Vaccines); 0 (Haemophilus influenzae type b polysaccharide vaccine)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170612
[Lr] Data última revisão:
170612
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161019
[St] Status:MEDLINE



página 1 de 106 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde